Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 10;41(11):1859-1863.
doi: 10.1016/j.vaccine.2022.12.069. Epub 2023 Jan 9.

Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022

Pedro L Moro  1 , Bicheng Zhang  2 , Carol Ennulat  2 , Margaret Harris  2 , Rachel McVey  2 , Gina Woody  2 , Paige Marquez  2 , Michael M McNeil  2 , John R Su  2
Affiliations
Review

Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022

Pedro L Moro et al. Vaccine. .

Abstract

Background: COVID-19 vaccines may be co-administered with other recommended vaccines, including seasonal influenza vaccines. However, few studies have evaluated the safety of co-administration of mRNA COVID-19 and seasonal influenza vaccines.

Objective: To describe reports to the Vaccine Adverse Event Reporting System (VAERS) after co-administration of mRNA COVID-19 and seasonal influenza vaccines.

Methods: We searched the VAERS database for reports of adverse events (AEs) following co-administration of mRNA COVID-19 and seasonal influenza vaccines and following a first booster dose mRNA COVID-19 vaccine alone, during July 1, 2021-June 30, 2022. We assessed the characteristics of these reports and described the most frequently reported MedDRA preferred terms (PTs). Clinicians reviewed available medical records for serious reports and reports of adverse events of special interest (AESI) and categorized the main diagnosis by system organ class.

Results: From July 1, 2021 through June 30, 2022, VAERS received 2,449 reports of adverse events following co-administration of mRNA COVID-19 and seasonal influenza vaccines. Median age of vaccinees was 48 years (IQR: 31, 66); 387 (15.8%) were classified as serious. Most reports (1,713; 69.3%) described co-administration of a first booster dose of an mRNA COVID-19 vaccine with seasonal influenza vaccine. The most common AEs among non-serious reports were injection site reactions (193; 14.5%), headache (181; 13.6%), and pain (171; 12.8%). The most common AEs among reports classified as serious were dyspnea (38; 14.9%), COVID-19 infection (32; 12.6%), and chest pain (27; 10.6%).

Discussion: This review of reports to VAERS following co-administration of mRNA COVID-19 and seasonal influenza vaccines did not reveal any unusual or unexpected patterns of AEs. Increased reporting of certain events (e.g., COVID-19 disease) was expected. CDC will continue to monitor the safety of co-administration of mRNA COVID-19 and seasonal influenza vaccines, including co-administration involving bivalent mRNA COVID-19 booster vaccines that have been recommended for people ages ≥ 6 months in the United States.

Keywords: Adverse events; COVID-19; Co-administration; Coronavirus; Epidemiology; Influenza vaccines; SARS-CoV-2; Surveillance; Vaccine safety; mRNA vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Most common reported MedDRA preferred terms after co-administration of mRNA COVID-19 booster dose and quadrivalent inactivated influenza (IIV4) vaccines (n = 1,019), and after mRNA COVID-19 booster dose vaccines administered alone (n = 59,384).
See this image and copyright information in PMC

References

    1. Oliver S.E., Gargano J.W., Marin M., et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922–1924. doi: 10.15585/mmwr.mm6950e. - DOI - PMC - PubMed
    1. Oliver S.E., Gargano J.W., Marin M., et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653–1656. doi: 10.15585/mmwr.mm695152e1. - DOI - PMC - PubMed
    1. Fleming-Dutra KE, Wallace M, Moulia DL, et al. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022. MMWR Morb Mortal Wkly Rep 2022;71:859–868. DOI: http://dx.doi.org/10.15585/mmwr.mm7126e2. - PubMed
    1. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. FDA News Release. August 31, 2022. Accessed October 10, 2022 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19....
    1. CDC Expands Updated COVID-19 Vaccines to Include Children Ages 5 Through 11. Accessed at https://www.cdc.gov/media/releases/2022/s1012-COVID-19-Vaccines.html.